Pulse Biosciences (PLSE) EBT (2015 - 2026)

Pulse Biosciences has reported EBT for 12 years, with the latest figure at -$24.7 million in Q2 2026.

• On a quarterly basis, EBT fell 28.71% year-over-year to -$24.7 million in Q2 2026; TTM through Jun 2026 was -$80.6 million, a 18.53% decrease from a year earlier, with the FY2025 full-year figure at -$72.7 million, down 35.73% from the prior year.
• EBT was -$24.7 million for Q2 2026 at Pulse Biosciences, down from -$17.4 million in the prior quarter.
• The five-year high for EBT was -$9.2 million in Q4 2022, with the low at -$24.7 million in Q2 2026.
• Average EBT over 5 years is -$14.8 million, with a median of -$14.0 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: EBT surged 43.26% in 2023, then tumbled 68.39% in 2025.
• Over 5 years, EBT stood at -$9.2 million in 2022, then decreased by 29.75% to -$11.9 million in 2023, then tumbled by 62.45% to -$19.4 million in 2024, then climbed by 10.1% to -$17.4 million in 2025, then tumbled by 41.57% to -$24.7 million in 2026.
• The last three EBT figures came in at -$24.7 million (Q2 2026), -$17.4 million (Q4 2025), and -$19.4 million (Q3 2025), per Business Quant data.